Yang Zhang

30PUBLICATIONS
164CO-AUTHORS
Molecular targetsGene and molecular therapyCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)Epigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (30)

|Oct 01, 2026
Development of A10P3C, an isoform-selective inhibitor of EGLN2, for targeting breast cancer.

|Jul 10, 2026
The MEK inhibitor trametinib incurs mitochondrial injury and induces innate immune responses in the mouse heart.

|Apr 01, 2026
Glucocorticoids elevate clear cell renal cell carcinoma sensitivity to HIF-2α inhibitors by suppressing H4K12 lactylation.

Kenan Zhang, Lin He, Yizhou Wang

|Mar 13, 2026
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.

James A C Bertlin, Tekle Pauzaite, Qian Liang

|Feb 04, 2026
ZNF395 Is a Hypoxia-Responsive Regulator of Mitochondrial Glutaminolysis in Clear Cell Renal Cell Carcinoma.

Joanna Koh, Chengheng Liao, Michelle Shu Wen Ng

|Nov 05, 2025
DLL1-responsive PD-L1+ tumor-associated macrophages promote endocrine resistance in breast cancer.

Shailesh Singh, Claudia Weindorfer, Ajeya Nandi

Pageof 5

Frequent Collaborators

10 joint publications

Chengheng Liao

8 joint publications

Jeremy Simon

6 joint publications

Lianxin Hu

5 joint publications

Jing Zhang